Kardigan closed at $14.13 on Oct 30, down 1.26%, 25.8% below its highest close since Sep 11. Volume of 452.8K shares was 0.75× its 20-day average (below normal).
Split-adjusted performance: -0.8% over one month.
Short interest was 5.3M shares at the Oct 15 settlement, up 19.3% from the prior report (13.8% of float, 7.6 days to cover).
No reported quarters with price history yet.
Percentile among 421 companies (100 = best)
Industry medians: 6-month return −24.3%, revenue growth +6.4%, net margin −35.1%, P/E 15.8×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| KARDKardigan | $14.13 | −1.26% | — | — | — | — | $1.32B | |
| DMRADamora Therapeutics | $21.49 | −2.36% | — | — | — | — | $1.33B | Compare |
| NKTRNektar Therapeutics | $38.87 | −0.79% | −55.0% | −9.3% | −401.0% | — | $1.33B | Compare |
| OMEROmeros | $18.44 | −2.69% | +22.4% | — | 46.4% | 10.7 | $1.33B | Compare |
| LBRXLB Pharmaceuticals | $39.70 | −1.12% | +26.3% | — | — | — | $1.28B | Compare |
| KRSAKorsana Biosciences | $30.14 | −0.26% | — | — | — | — | $1.37B | Compare |
| OPKOpko Health | $1.66 | 0.00% | +50.9% | +4.3% | −5.1% | — | $1.24B | Compare |
| RAPPRapport Therapeutics | $25.05 | +3.47% | −26.1% | — | — | — | $1.41B | Compare |
| SNDXSyndax Pharmaceuticals | $13.65 | −3.53% | −28.6% | +91.8% | −67.8% | — | $1.22B | Compare |
No recent articles focused on Kardigan. 1 articles mention it in passing.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
